Objective: To investigate the effects of Hedan Tablet（荷丹片） on serum lipid profile, proprotein convertase subtilisin/kexin type 9（PSCK9） and high-density lipoprotein（HDL） subfractions in patients with hyperlipidemia. Methods: Thirty-seven patients with hyperlipidemia were randomized to treatment with Hedan Tablet 4.38 g/day as Hedan group（18 cases） or placebo（19 cases） as control group for 8 weeks. The lipid profile, PCSK9 and HDL subfractions were determined at day 0 and week 8 in both groups re... 

【文章來源】：Chinese Journal of Integrative Medicine. 2016,22(09)SCICSCD

【文章頁數(shù)】：6 頁

【參考文獻(xiàn)】：
期刊論文
[1]荷丹片聯(lián)合阿托伐他汀對(duì)頸動(dòng)脈粥樣硬化患者炎性細(xì)胞因子的干預(yù)影響[J]. 陳亞麗.  中西醫(yī)結(jié)合心腦血管病雜志. 2012(07)
[2]The New Strategy for Modulating Dyslipidemia:Consideration from Updated Understanding on High-Density Lipoprotein[J]. 文川,徐浩.  Chinese Journal of Integrative Medicine. 2011(06)
[3]Progress of Research in Treatment of Hyperlipidemia by Monomer or Compound Recipe of Chinese Herbal Medicine[J]. 竇曉兵,沃興德,范春雷.  Chinese Journal of Integrative Medicine. 2008(01)
[4]荷丹片的降血脂作用[J]. 萬阜昌,黃道齋.  中國實(shí)驗(yàn)方劑學(xué)雜志. 1996(01)



本文編號(hào)：3104159